70%-80% of diagnostic decisions are based on laboratory tests. The correct interpretation of laboratory results allows a doctor to distinguish "healthy" from "diseased". Laboratory test results are the most important parameter for the diagnosis and monitoring of all pathological conditions. Decrease: - Medications: Non-steroidal anti-inflammatory, steroids, salicylates, statins, angiotensin-converting enzyme (ACE) inhibitors together with beta-blocker. Medications: Oral contraceptives (false positive). Alzheimer's disease, ankylosing spondylitis, Castleman's disease, gout, Graves disease, Hodgkin's disease, Kawasaki disease, lymphoma, malignant tumors, metabolic syndrome, myocardial infarction, myxoma, necrosis, non-Hodgkin's disease, postoperative (first week), pregnancy (after the third month), renal infarction, systemic lupus erythematosus, trauma (surgical), tuberculosis. Increase: Active inflammatory conditions such as, bronchitis, abscess, Crohn's disease, empyema, meningitis, nephritis, pancreatitis (acute), peritonitis, pharyngitis (streptococcal), pneumonia (pneumococcal), rheumatoid arthritis (acute), rheumatic fever (acute), sepsis, urinary tract infection and other infections.A reduction of CRP by 25% or more from the previous day's level indicates a recession of inflammation, with a predictive value of more than 97%. Daily measurement of C-Reactive Protein is an excellent indicator for monitoring the recession of inflammation. It is a more reliable indicator than ESR for assessing inflammatory conditions. CRP measurement can be used as a "tool" to evaluate patients at risk of developing heart disease.ĬRP measurement is used to monitor inflammatory processes of rheumatoid arthritis and rheumatic fever, to differentiate Crohn's disease (high CRP) from ulcerative colitis (low CRP), to differentiate rheumatoid arthritis (high CRP) from systemic lupus erythematosus (low CRP), as a prognostic indicator of myocardial infarction and coronary heart disease, as an indicator for existing arterial diseases, in detecting the presence or exacerbation of inflammatory processes, and in monitoring the response to treatment of inflammatory conditions. It is now thought that chronic inflammation, as evidenced by chronically elevated levels of C-reactive protein, may be an additional component of metabolic syndrome. The C-reactive protein has been linked to metabolic syndrome, a group of symptoms that include abdominal obesity, hypertriglyceridemia, low HDL (good cholesterol), hypertension, and high fasting blood glucose levels. It is the best indicator of the severity of pancreatitis when measured 48 hours after the onset of symptoms. Because it disappears rapidly when the inflammation subsides, its detection is indicative of the presence of the inflammatory process. CRP is detectable within 6-10 hours after the body's inflammatory response and can increase up to 4.000 times when the acute phase inflammatory response is at its peak. The hsCRP assay is being increasingly used as a marker for cardiac risk assessment and as a prognostic tool in heart disease.Ĭ-reactive protein (CRP) is a serum glycoprotein produced by the liver during any acute inflammation. These results “provide a test that is easy to perform and may be used widely in various clinics to predict AS to aid in early diagnosis and treatment,” they concluded.The high-sensitivity C-reactive protein (hsCRP) assay is a quantitative analysis test of very low levels of C-reactive protein (CRP) in the blood. “In this large-scale, community-based, prospective study, baseline plasma concentrations of (CRP) were predictive of the future risk of AS over an average follow-up period of 8 years,” the researchers wrote. Researchers found similar results when they excluded AS cases that occurred in the first two years of follow-up, and when they analyzed subgroups that were stratified by gender and age. Results revealed that baseline CRP levels were positively associated with the risk of developing AS. Compared with subjects with CRP levels of less than 1 mg/L, the risk of developing AS was 1.28-fold higher for subjects with CRP levels of 1.00–2.99 mg/L, 4.71-fold higher for subjects with CRP levels of 3.00–9.99 mg/L, and 19.8-fold higher for subjects with CRP levels of 10.00 mg/L or more. Using statistical models, researchers were able to calculate the risk of developing AS on the basis of high CRP concentrations after adjusting for various factors including age, gender, smoking status, alcohol consumption, physical activity, body mass index, blood pressure, glucose and cholesterol levels, history of cardiovascular disease, use of antihypertensive medication, lipid-lowering drugs, and aspirin.Ī total of 55 subjects developed AS at follow-up (approximately eight years).
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |